Patents Examined by Jeffrey E. Russel
  • Patent number: 11564905
    Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by administering to the subject a pharmaceutical composition comprising a kallikrein 5 (KLK5) inhibitor, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: January 31, 2023
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Nurit P. Azouz, Marc E. Rothenberg
  • Patent number: 11559561
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: January 24, 2023
    Assignee: TRANSLATE BIO, INC.
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Patent number: 11554157
    Abstract: The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: January 17, 2023
    Assignee: NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION
    Inventors: Snezna Rogelj, Danielle Nicole Turner
  • Patent number: 11555052
    Abstract: This disclosure relates to methods for the prevention of the reduction of disulfide bonds in a polypeptide expressed in a recombinant host cell, comprising, following fermentation, adding selenite and/or its salts or derivatives to a harvest solution of the recombinant host cell, wherein the disulfide bond in the polypeptide remains non-reduced.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: January 17, 2023
    Assignee: Bayer HealthCare LLC
    Inventor: Kathryn Kwant
  • Patent number: 11548916
    Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: January 10, 2023
    Assignee: Eberhard Karls Universitaet Tuebingen
    Inventors: Bernhard Krismer, Andreas Peschel, Stephanie Grond, Alexander Zipperer, Martin Christoph Konnerth, Daniela Janek, Hubert Kalbacher, Nadine Anna Schilling
  • Patent number: 11547688
    Abstract: Nootropic compositions and methods of providing or using the same are provided herewith. Some preferred compositions include a combination of free amino acids and one or more peptides. Compositions may optionally include one or more of an anti-adherent, a B vitamin, shilajit, a sugar, a fatty acid, ashwaganda, ginseng, or rodiola, among other things.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: January 10, 2023
    Inventor: Nodari Rizun
  • Patent number: 11529398
    Abstract: This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: December 20, 2022
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Janos Csikos, Irena Pulte, Michael Althaus, Markus Krueer, Nico Wegener
  • Patent number: 11529421
    Abstract: Certain aspects of the present invention relate to modified hemoglobin proteins comprising at least one modification (e.g., at the thiol group of an exogenous amino acid residue) for homogenous conjugation of one or more polymeric moieties e.g. polyethylene glycol or derivatives thereof. Also included herein are methods of using such modified proteins and compositions comprising such proteins, e.g. in therapy.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 20, 2022
    Assignee: University of Essex Enterprises Limited
    Inventors: Chris E. Cooper, Brandon Reeder, Gary Silkstone
  • Patent number: 11518794
    Abstract: A synthesis method for low-racemization impurity liraglutide comprises the following steps: performing synthesis to obtain a propeptide, coupling 2 to 5 peptides comprising Thr-Phe on the propeptide by using a solid-phase synthesis method; further, performing solid-phase synthesis to obtain a liraglutide resin; the liraglutide resin is cracked after modification, or the liraglutide resin is directly cracked, purified and frozen dry, so as to obtain the liraglutide.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 6, 2022
    Assignee: SHENZHEN JYMED TECHNOLOGY CO., LTD.
    Inventors: Yuqing Fu, Hongji Ma, Xinyu Li, Lixiang Zhang, Qin Zhi, Lifen Wu, Zicheng Liu
  • Patent number: 11517609
    Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: December 6, 2022
    Assignee: Xellia Pharmaceuticals ApS
    Inventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
  • Patent number: 11510962
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, a and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 29, 2022
    Assignee: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Patent number: 11510969
    Abstract: Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 29, 2022
    Assignee: MEDLINE INDUSTRIES, LP
    Inventors: Debashish Chakravarthy, Brian Mattorano, Anthony Frei
  • Patent number: 11479581
    Abstract: The disclosure is directed to compounds and methods for preparing purified macrocyclic peptide using “catch-release” methods. These methods comprise reacting a free amino group of a resin-bound linear peptide with an azide- or alkyne-functionalized cap to form a resin-bound capped linear peptide having an azide- or alkyne-functionalized cap; cleaving the capped linear peptide from the resin to form a free capped linear peptide having an azide- or alkyne-functionalized cap; reacting the free capped linear peptide having an azide-functionalized cap with an alkyne-functionalized catch resin, or reacting the free capped linear peptide having an akynyl-functionalized cap with an azide functionalized catch resin, to form a catch-resin bound capped linear peptide; reacting the catch-resin bound capped linear peptide under conditions sufficient to effect macrocyclization of the linear peptide and release of the macrocyclic peptide from the catch resin.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: October 25, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gardner S. Creech, Mahboubeh Kheirabadi, Martin D. Eastgate, David S. Nirschl, Percy H. Carter
  • Patent number: 11479596
    Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 25, 2022
    Assignees: YUHAN CORPORATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Moo Young Song, Taejin Yoon, Jung-Sun Lee, Byung Hyun Choi, In Hwan Lim, Man Sil Park, Jin-Hyoung Lee, Hyoung Sig Seo, Hyeon Woo Kang, Sung Ho Kim, Eun Jig Lee, Jin Sook Yoon, Cheol Ryong Ku
  • Patent number: 11472857
    Abstract: The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: October 18, 2022
    Assignee: Purdue Research Foundation
    Inventors: Elizabeth M. Murphy Topp, Hamed Tabatabaei Ghomi, Markus Lill, Shenbaga Moorthy Balakrishnan
  • Patent number: 11472835
    Abstract: The present invention describes the integration of preparative crystallization, crystal separation, crystal washing and freeze-drying processes of insulin and insulin analogues into single continuous process using pressure filtration. The process facilitates time reduction and outlines the novel design of using multiple organic solvent washes and nitrogen gas purging for the removal of imbibed water and achieve final drug substance that meets the quality specifications.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: October 18, 2022
    Inventors: Sai Srikar Kandukuri, Vibhava Shukla, Arul Marimuthu, Mukul Pathy, Partha P. Hazra
  • Patent number: 11472846
    Abstract: A method for treating a cancer comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising an anti-cancer agent having at least one secretion modifying region (SMR) peptide from HIV-1 Nef fused to at least one cell-penetrating peptide (CPP) or at least one Clusterin (Clu)-binding peptide (Clu-BP).
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: October 18, 2022
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent C. Bond, James W. Lillard, Jr., Ming Bo Huang
  • Patent number: 11459373
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using anion exchange chromatography to produce aflibercept with a specific glycosylation profile. In particular, these methods produce aflibercept with a glycosylation profile with specific ranges of % total fucosylated glycans, total sialylated glycans, mannose-5, and galactosylated glycans.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: October 4, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
  • Patent number: 11459357
    Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 4, 2022
    Assignee: SPERO THERAPEUTICS, INC.
    Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Dean Rivers, Roy Lester, Scott Coleman
  • Patent number: 11459374
    Abstract: The present disclosure pertains to methods for preparing a prefilled syringe and methods for preparing an auto injector prefilled syringe comprising aflibercept and methods for producing such aflibercept in chemically defined media.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: October 4, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li